FITC标记的载脂蛋白A1抗体-抗体-抗体-生物在线
上海沪震实业有限公司
FITC标记的载脂蛋白A1抗体

FITC标记的载脂蛋白A1抗体

商家询价

产品名称： FITC标记的载脂蛋白A1抗体

英文名称： Anti-APOA1/FITC

产品编号： HZ-2314R-FITC

产品价格： null

产品产地： 中国/上海

品牌商标： HZbscience

更新时间： 2023-08-17T10:24:20

使用范围： IF=1:50-200

上海沪震实业有限公司
  • 联系人 : 鲍丽雯
  • 地址 : 上海市闵行区闵北路88弄1-30号第22幢AQ136室
  • 邮编 : 200612
  • 所在区域 : 上海
  • 电话 : 139****0749 点击查看
  • 传真 : 点击查看
  • 邮箱 : www.shzbio.net
  • 二维码 : 点击查看
进入展台

 Rabbit Anti-APOA1/FITC Conjugated antibody

FITC标记的载脂蛋白A1抗体

 

英文名称 Anti-APOA1/FITC
中文名称 FITC标记的载脂蛋白A1抗体
别    名 Apo-AI; ApoA I; ApoA-I; APOA1_HUMAN; Apolipoprotein A-I(1-242); Apolipoprotein A1; Apolipoprotein A 1; Apolipoprotein AI; Apolipoprotein A I; Brp14; Ltw1; Lvtw1; Sep1; Sep2.  
规格价格 100ul/2980元 购买        大包装/询价
说 明 书 100ul  
研究领域 肿瘤  心血管  细胞生物  免疫学  神经生物学  信号转导  脂蛋白  新陈代谢  
抗体来源 Rabbit
克隆类型 Polyclonal
交叉反应 Human, Mouse, 
产品应用 IF=1:50-200  
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 27kDa
性    状 Lyophilized or Liquid
浓    度 1mg/ml
免 疫 原 KLH conjugated synthetic peptide derived from human APOA1
亚    型 IgG
纯化方法 affinity purified by Protein A
储 存 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
产品介绍 background:
Apolipoprotein A I promotes cholesterol efflux from tissues to the liver for excretion. Apolipoprotein A I is the major protein component of high density lipoprotein (HDL) in the plasma. Synthesized in the liver and small intestine, it consists of two identical chains of 77 amino acids; an 18 amino acid signal peptide is removed co-translationally and a 6 amino acid propeptide is cleaved post-translationally. Apolipoprotein A I is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. Defects in the Apolipoprotein A I gene are associated with HDL deficiency and Tangier disease. The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I. The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases.

Function:
Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility.

Subunit:
Interacts with APOA1BP and CLU. Component of a sperm activating protein complex (SPAP), consisting of APOA1, an immunoglobulin heavy chain, an immunoglobulin light chain and albumin. Interacts with NDRG1.

Subcellular Location:
Secreted.

Tissue Specificity:
Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine.

Post-translational modifications:
Palmitoylated.
Phosphorylation sites are present in the extracelllular medium.

DISEASE:
Defects in APOA1 are a cause of high density lipoprotein deficiency type 2 (HDLD2) [MIM:604091]; also known as familial hypoalphalipoproteinemia (FHA). Inheritance is autosomal dominant.
Defects in APOA1 are a cause of the low HDL levels observed in high density lipoprotein deficiency type 1 (HDLD1) [MIM:205400]; also known as analphalipoproteinemia or Tangier disease (TGD). HDLD1 is a recessive disorder characterized by the absence of plasma HDL, accumulation of cholesteryl esters, premature coronary artery disease, hepatosplenomegaly, recurrent peripheral neuropathy and progressive muscle wasting and weakness. In HDLD1 patients, ApoA-I fails to associate with HDL probably because of the faulty conversion of pro-ApoA-I molecules into mature chains, either due to a defect in the converting enzyme activity or a specific structural defect in Tangier ApoA-I.
Defects in APOA1 are the cause of amyloid polyneuropathy-nephropathy Iowa type (AMYLIOWA) [MIM:107680]; also known as amyloidosis van Allen type or familial amyloid polyneuropathy type III. AMYLIOWA is a hereditary generalized amyloidosis due to deposition of amyloid mainly constituted by apolipoprotein A1. The clinical picture is dominated by neuropathy in the early stages of the disease and nephropathy late in the course. Death is due in most cases to renal amyloidosis. Severe peptic ulcer disease can occurr in some and hearing loss is frequent. Cataracts is present in several, but vitreous opacities are not observed. Defects in APOA1 are a cause of amyloidosis type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash.

Similarity:
Belongs to the apolipoprotein A1/A4/E family.

Database links:

Entrez Gene: 335 Human

Omim: 107680 Human

SwissProt: P02647 Human

Unigene: 93194 Human



Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

APOA1是检测高密度脂蛋白的主要形式，APOA1降低被认为是心、脑血管疾病的危险因素。
APOA1升高：常见于肝脏疾病、肝外胆道阻塞、人工透析。
APOA1降低：常见于冠心病、未控制的糖尿病、肾病综合征、营养不良、活动性肝炎、肝功能低下、动脉粥样硬化、高脂蛋白血症
   

载脂蛋白A I促进胆固醇流出从组织到肝脏排泄。载脂蛋白A-Ⅰ是血浆中高密度脂蛋白（HDL）的主要蛋白组分。在肝脏和小肠中合成，它由两个相同的77个氨基酸链组成，共18个氨基酸信号肽被翻译掉，翻译后的6个氨基酸前肽被裂解。载脂蛋白A I是卵磷脂胆固醇酰基转移酶（LCAT）的辅助因子，它负责形成大多数血浆胆甾醇酯。载脂蛋白AI基因的缺陷与HDL缺乏和丹吉尔病有关。APOA-Ⅰ的治疗潜力最近已在急性冠状动脉综合征患者中评估，使用重组形式的APOA-Ⅰ的自然发生变异体Ⅰ。重组正常APOA-Ⅰ的可用性有助于进一步研究APOA的潜在有用性。我在预防动脉粥样硬化性血管疾病。